Eager capital prompts IPO plans for more Chinese makers of brain-computer interfaces
A handful of home-grown Chinese companies involved in brain computer interfaces (BCIs) are moving towards initial public offerings (IPOs) on onshore markets, taking advantage of the sector’s status as a new darling of private capital. The trend fits into a broad pattern of hi-tech firms flocking to list on the Shanghai Stock Exchange’s Nasdaq-style Star Market. Among the BCI hopefuls,…
Chinese companies specializing in brain-computer interfaces (BCIs) are increasingly pursuing initial public offerings (IPOs) on domestic markets, capitalizing on the sector's recent surge in popularity. Shanghai-based Arfysica Innovation has recently registered for IPO coaching, aiming for a listing on the Shanghai Stock Exchange's Nasdaq-style Star Market.
The BCI industry involves translating brain signals into commands for external devices like computers or robotic limbs, with companies like Elon Musk's Neuralink leading the charge.
Founded in 2015 with a registered capital of 100 million yuan (US$15 million), Arfysica is led by founder Wang Wei, who owns 51% of the company and serves as its legal representative. Wang holds a bachelor's degree from Tianjin University and a PhD in biomedical engineering from the University of Southampton, having previously worked at Siemens Healthcare.
BCI advancements have garnered significant attention, with Shanghai-based Neuracle Medical Technology also preparing for an IPO. Neuracle gained regulatory approval for an implantable BCI system designed to aid spinal cord injury patients in regaining hand movement, having raised 72 million yuan in five rounds of investment. Other Chinese BCI companies, such as BrainCo, are also eyeing onshore IPOs.
BrainCo, which collaborates with Beijing's Capital Medical University on BCI products for depression screening, has filed confidentially for a Hong Kong IPO. The IPO market currently features companies with higher innovation levels, stronger capital backing, and increased research-and-development spending compared to previous years, according to Morgan Stanley.
As of mid-2026, 106 companies had listed on the Star Market, raising approximately 281 billion yuan.
Written by urgent.news from SCMP Business's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
